Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-PDL-1 antibody · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Anti-PDL-1 antibody (Arm 1) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 2) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 3) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 4) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Anti-PDL-1 antibody (Arm 5) | EXPERIMENTAL | BMS-936559 (MDX-1105) |
| Name | Type | Description |
|---|---|---|
| Anti-PDL-1 antibody | BIOLOGICAL | Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 * The malignancies include relapsed/refractory renal cell carcinoma, non-small cell lung cancer, colorectal adenocarcinoma, malignant melanoma, advanced/metastatic epithelial ovarian cancer, gastric cancer, pa...
Anti-PDL-1 antibody is an investigational monoclonal antibody being developed for the treatment of cancer, including multiple indications. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Anti-PDL-1 antibody is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY.
Anti-PDL-1 antibody is in Phase 1 clinical development. It is an investigational drug and has not been approved for commercial use. One Phase 1 trial has been completed.
Anti-PDL-1 antibody has one completed clinical trial, NCT00729664, titled 'Multiple Ascending Dose (MDX1105-01)'. This Phase 1 study enrolled 281 participants with cancer and multiple indications in the United States.
Anti-PDL-1 antibody targets the programmed death-ligand 1 (PD-L1) protein. By binding to PD-L1, it is designed to modulate immune responses in the treatment of cancer.